Co-Development and License Agreement Sample Contracts

AutoNDA by SimpleDocs
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. CO-DEVELOPMENT AND LICENSE AGREEMENT Between...
Co-Development and License Agreement • May 28th, 2021 • Ambrx Biopharma Inc. • Biological products, (no disgnostic substances)

This CO-DEVELOPMENT AND LICENSE AGREEMENT (this “Agreement”), effective as of June 14, 2013 (the “Effective Date”), is between AMBRX, Inc., a Delaware Corporation having the principal business address at 10975 North Torrey Pine Road, La Jolla, California 92037, USA for and on behalf of itself and its Affiliates (together with its Affiliates, “AMBRX”), and , Zhejiang Medicine Co., Ltd., a company duly organized and existing under the laws of the People’s Republic of China and having the principal business address at 268 Dengyun Road, Gongshu District, Hangzhou, Zhejiang, P.R. China, for and on behalf of itself and its Affiliates (together with its Affiliates, “ZMC”). AMBRX and ZMC may each be referred to herein individually as a “Party” or, collectively, as the “Parties.”

Co-development and License Agreement on NIP-022, a Novel Platelet Increasing Agent
Co-Development and License Agreement • October 26th, 2015

Nissan Chemical Industries, Ltd. (Tokyo, Japan, President: Kojiro Kinoshita, “Nissan”) and Yakult Honsha Co., Ltd. (Tokyo, Japan, President: Takashige Negishi, “Yakult”) are pleased to announce that both companies have entered into a co-development and license agreement on NIP-022, a novel platelet increasing agent discovered by Nissan.

CO-DEVELOPMENT AND LICENSE AGREEMENT BY AND BETWEEN JANSSEN PHARMACEUTICA, N.V. AND MINERVA NEUROSCIENCES, INC. DATED FEBRUARY 13, 2014
Co-Development and License Agreement • June 10th, 2014 • Minerva Neurosciences, Inc. • Pharmaceutical preparations • New York

THIS CO-DEVELOPMENT AND LICENSE AGREEMENT (the “Agreement”), executed as of February 13, 2014 (the “Execution Date”), is made by and between Janssen Pharmaceutica, N.V., a corporation organized and existing under the laws of Belgium, having its principal place of business is at Turnhoutseweg 30, 2340 Beerse, Belgium (hereinafter “Janssen”), and Minerva Neurosciences, Inc., a corporation organized under the laws of the State of Delaware, having its principal place of business at 245 First Street, Cambridge, Massachusetts (hereinafter “Minerva”). Janssen and Minerva are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”

Arena, Ildong Pharma enter deal in South Korea
Co-Development and License Agreement • December 10th, 2022
CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CO-DEVELOPMENT AND LICENSE...
Co-Development and License Agreement • June 23rd, 2014 • Ambrx Inc • Pharmaceutical preparations • Hong Kong

This CO-DEVELOPMENT AND LICENSE AGREEMENT (this “Agreement”), effective as of April 10, 2014 (the “Effective Date”), is between Ambrx, Inc., a Delaware Corporation having its principal business address at 10975 North Torrey Pine Road, La Jolla, California 92037, USA for and on behalf of itself and its Affiliates (together with its Affiliates, “AMBRX”), and Zhejiang HISUN Pharmaceutical Co., Ltd., a company duly organized and existing under the laws of the People’s Republic of China and having its principal business address at 46 Waisha Road, Jiaojiang District, Taizhou City, Zhejiang Province, 318000, P.R. China, for and on behalf of itself and its Affiliates (together with its Affiliates, “HISUN”). AMBRX and HISUN may each be referred to herein individually as a “Party” or, collectively, as the “Parties.”

CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CO-DEVELOPMENT AND LICENSE...
Co-Development and License Agreement • June 23rd, 2014 • Ambrx Inc • Pharmaceutical preparations

This CO-DEVELOPMENT AND LICENSE AGREEMENT (this “Agreement”), effective as of June 14, 2013 (the “Effective Date”), is between AMBRX, Inc., a Delaware Corporation having the principal business address at 10975 North Torrey Pine Road, La Jolla, California 92037, USA for and on behalf of itself and its Affiliates (together with its Affiliates, “AMBRX”), and , Zhejiang Medicine Co., Ltd., a company duly organized and existing under the laws of the People’s Republic of China and having the principal business address at 268 Dengyun Road, Gongshu District, Hangzhou, Zhejiang, P.R. China, for and on behalf of itself and its Affiliates (together with its Affiliates, “ZMC”). AMBRX and ZMC may each be referred to herein individually as a “Party” or, collectively, as the “Parties.”

CO-DEVELOPMENT AND LICENSE AGREEMENT among NOVOCODEX BIOPHARMACEUTICALS LTD. and AMBRX, INC. Dated as of 22 October, 2019
Co-Development and License Agreement • May 28th, 2021 • Ambrx Biopharma Inc. • Biological products, (no disgnostic substances) • Hong Kong

This CO-DEVELOPMENT AND LICENSE AGREEMENT (this “Agreement”), effective as of 22 October, 2019 (the “Effective Date”), is between, Ambrx, Inc., a Delaware corporation having its principal business address at 10975 North Torrey Pines Road, La Jolla, California 92037, USA, for and on behalf of itself and its Affiliates (together with its Affiliates, “Ambrx”), and NovoCodex Biopharmaceuticals Ltd., a company registered under the laws of the People’s Republic of China, with its registered address in Shaoxing, China, for and on behalf of itself and its Affiliates (together with its Affiliates, “Novocodex”). Novocodex currently is majority owned by Zhejiang Medicine Co. Ltd., a company registered with address in Shaoxing, China. Ambrx and Novocodex may each be referred to herein individually as a “Party” or, collectively, as the “Parties.”

CO-DEVELOPMENT AND LICENSE AGREEMENT between NEOTHERAPEUTICS, INC. and GPC BIOTECH AG Dated as of September 30, 2002
Co-Development and License Agreement • June 9th, 2004 • GPC Biotech Ag • Massachusetts

This CO-DEVELOPMENT AND LICENSE AGREEMENT (this “Agreement”), dated as of September 30, 2002, is between Neotherapeutics, Inc., a company duly organized and existing under the laws of Delaware and having offices at 157 Technology Drive, Irvine, California, USA for and on behalf of itself and its Affiliates (“NEOTHERAPEUTICS”), and GPC Biotech AG, a company duly organized and existing under the laws of the Federal Republic of Germany and having offices at Fraunhoferstrasse 20, D-82152 Martinsried/Munich Germany, for and on behalf of itself and its Affiliates (together with its Affiliates, “GPC”).

CO-DEVELOPMENT AND LICENSE AGREEMENT
Co-Development and License Agreement • March 16th, 2006 • Pharmion Corp • Pharmaceutical preparations • New York

This Co-Development and License Agreement (the “Agreement”) is made and entered into effective as of December 19, 2005 (the “Effective Date”) by and between GPC Biotech AG, a German corporation, having its place of business at Fraunhoferstrasse 20, 82152 Martinsried/Munich, Germany (“GPC Biotech”); and Pharmion GmbH, a Swiss limited liability company and wholly-owned subsidiary of Pharmion Corporation, a Delaware corporation, having a place of business at Aeschenvorstadt 71, 4051 Basel, Switzerland (“Licensee”). GPC Biotech and Licensee are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”

CO-DEVELOPMENT AND LICENSE AGREEMENT
Co-Development and License Agreement • April 26th, 2011 • Cell Therapeutics Inc • Pharmaceutical preparations • England and Wales

** Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

CO-DEVELOPMENT AND LICENSE AGREEMENT between SINO BIOPHARMACEUTICAL CO., LTD. and AMBRX, INC. Dated as of January 13, 2020
Co-Development and License Agreement • May 28th, 2021 • Ambrx Biopharma Inc. • Biological products, (no disgnostic substances) • Hong Kong

This CO-DEVELOPMENT AND LICENSE AGREEMENT (this “Agreement”), effective as of January 13, 2020 (the “Effective Date”), is between Ambrx, Inc., a Delaware corporation having its principal business address at 10975 North Torrey Pines Road, La Jolla, California 92037, USA, for and on behalf of itself and its Affiliates (together with its Affiliates, “Ambrx”), and Sino Biopharmaceutical Co., Ltd., a company registered under the laws of the Cayman Islands, with its registered address in Cricket Square, Hutchins Drive, P.O. Box 2681, Grand Cayman, KY1-1111, Cayman Islands, for and on behalf of itself and its Affiliates (together with its Affiliates, “Sino”). Ambrx and Sino may each be referred to herein individually as a “Party” or, collectively, as the “Parties.”

CO-DEVELOPMENT AND LICENSE AGREEMENT RELATING TO IPH2201
Co-Development and License Agreement • September 20th, 2019 • Innate Pharma SA • Biological products, (no disgnostic substances) • England and Wales

THIS SECOND AMENDMENT TO THE CO-DEVELOPMENT AND LICENSE AGREEMENT RELATING TO IPH2201 (this “Second Amendment”) is made and entered into as of July 26, 2019 (the “Amendment Effective Date”), by and between MedImmune Limited, a company organized under the laws of England and Wales (“MedImmune”) and Innate Pharma S.A, a company organized under the laws of France (“Innate”). MedImmune and Innate are each referred to in this Amendment as a “Party” and collectively, as the “Parties”.

AMENDMENT NO. 1 TO CO-DEVELOPMENT AND LICENSE AGREEMENT
Co-Development and License Agreement • June 14th, 2017 • Minerva Neurosciences, Inc. • Pharmaceutical preparations • New York

This AMENDMENT NO. 1 TO CO-DEVELOPMENT AND LICENSE AGREEMENT (this “Amendment”), dated as of June 13, 2017 (the “Amendment Execution Date”), is made by and between Janssen Pharmaceutica NV, a corporation organized and existing under the laws of Belgium (“Janssen”) and Minerva Neurosciences, Inc., a corporation organized under the laws of the State of Delaware (“Minerva”). Janssen and Minerva are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”

CO-DEVELOPMENT AND LICENSE AGREEMENT
Co-Development and License Agreement • April 3rd, 2006 • GPC Biotech Ag • Pharmaceutical preparations • New York

This Co-Development and License Agreement (the “Agreement”) is made and entered into effective as of December 19, 2005 (the “Effective Date”) by and between GPC Biotech AG, a German corporation, having its place of business at Fraunhoferstrasse 20, 82152 Martinsried/Munich, Germany (“GPC Biotech”); and Pharmion GmbH, a Swiss limited liability company and wholly-owned subsidiary of Pharmion Corporation, a Delaware corporation, having a place of business at Aeschenvorstadt 71, 4051 Basel, Switzerland (“Licensee”). GPC Biotech and Licensee are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”

Contract
Co-Development and License Agreement • August 3rd, 2016 • CytomX Therapeutics, Inc. • Pharmaceutical preparations • Delaware

***Text Omitted and Filed Separately with the Securities and ExchangeExhibit 10.1 Commission. Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!